ARGX
Price
$877.94
Change
-$11.55 (-1.30%)
Updated
Dec 12 closing price
Capitalization
54.52B
75 days until earnings call
Intraday BUY SELL Signals
SBMFF
Price
$0.87
Change
-$0.00 (-0.00%)
Updated
Nov 26 closing price
Capitalization
15.63B
Intraday BUY SELL Signals
Interact to see
Advertisement

ARGX vs SBMFF

Header iconARGX vs SBMFF Comparison
Open Charts ARGX vs SBMFFBanner chart's image
argenx SE
Price$877.94
Change-$11.55 (-1.30%)
Volume$288.78K
Capitalization54.52B
Sino Biopharmaceutical
Price$0.87
Change-$0.00 (-0.00%)
Volume$202
Capitalization15.63B
ARGX vs SBMFF Comparison Chart in %
ARGX
Daily Signal:
Gain/Loss:
SBMFF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 114.69B. VRTX holds the highest valuation in this group at 114.69B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 65%. NBY experienced the highest price growth at 158%, while BPTSY experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -11%. For the same stocks of the Industry, the average monthly volume growth was -7% and the average quarterly volume growth was 72%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 80
Price Growth Rating: 54
SMR Rating: 92
Profit Risk Rating: 93
Seasonality Score: 17 (-100 ... +100)

Market Cap

The average market capitalization across the group is 35.48B. The market cap for tickers in the group ranges from 15.47B to 55.48B. ARGX holds the highest valuation in this group at 55.48B. The lowest valued company is SBMFF at 15.47B.

High and low price notable news

The average weekly price growth across all stocks in the group was -1%. For the same group, the average monthly price growth was 0%, and the average quarterly price growth was 39%. SBMFF experienced the highest price growth at 0%, while ARGX experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the group was 42%. For the same stocks of the group, the average monthly volume growth was -1% and the average quarterly volume growth was -47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 41
P/E Growth Rating: 55
Price Growth Rating: 43
SMR Rating: 66
Profit Risk Rating: 55
Seasonality Score: -12 (-100 ... +100)
VS
ARGX vs. SBMFF commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Buy and SBMFF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (ARGX: $889.49 vs. SBMFF: $0.87)
Brand notoriety: ARGX and SBMFF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGX: 87% vs. SBMFF: 36%
Market capitalization -- ARGX: $54.52B vs. SBMFF: $15.63B
ARGX [@Biotechnology] is valued at $54.52B. SBMFF’s [@Biotechnology] market capitalization is $15.63B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGX’s FA Score shows that 1 FA rating(s) are green whileSBMFF’s FA Score has 1 green FA rating(s).

  • ARGX’s FA Score: 1 green, 4 red.
  • SBMFF’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARGX and SBMFF are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGX’s TA Score shows that 4 TA indicator(s) are bullish while SBMFF’s TA Score has 4 bullish TA indicator(s).

  • ARGX’s TA Score: 4 bullish, 4 bearish.
  • SBMFF’s TA Score: 4 bullish, 1 bearish.
According to our system of comparison, SBMFF is a better buy in the short-term than ARGX.

Price Growth

ARGX (@Biotechnology) experienced а -2.89% price change this week, while SBMFF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

ARGX is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGX($54.5B) has a higher market cap than SBMFF($15.6B). ARGX has higher P/E ratio than SBMFF: ARGX (37.55) vs SBMFF (28.49). SBMFF YTD gains are higher at: 112.035 vs. ARGX (44.633). SBMFF has higher annual earnings (EBITDA): 6.98B vs. ARGX (966M). SBMFF has higher revenues than ARGX: SBMFF (26.2B) vs ARGX (3.61B).
ARGXSBMFFARGX / SBMFF
Capitalization54.5B15.6B349%
EBITDA966M6.98B14%
Gain YTD44.633112.03540%
P/E Ratio37.5528.49132%
Revenue3.61B26.2B14%
Total Cash3.93BN/A-
Total Debt43.2MN/A-
FUNDAMENTALS RATINGS
ARGX vs SBMFF: Fundamental Ratings
ARGX
SBMFF
OUTLOOK RATING
1..100
7342
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
11100
SMR RATING
1..100
3895
PRICE GROWTH RATING
1..100
4146
P/E GROWTH RATING
1..100
7535
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBMFF's Valuation (2) in the null industry is significantly better than the same rating for ARGX (81) in the Pharmaceuticals Other industry. This means that SBMFF’s stock grew significantly faster than ARGX’s over the last 12 months.

ARGX's Profit vs Risk Rating (11) in the Pharmaceuticals Other industry is significantly better than the same rating for SBMFF (100) in the null industry. This means that ARGX’s stock grew significantly faster than SBMFF’s over the last 12 months.

ARGX's SMR Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for SBMFF (95) in the null industry. This means that ARGX’s stock grew somewhat faster than SBMFF’s over the last 12 months.

ARGX's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as SBMFF (46) in the null industry. This means that ARGX’s stock grew similarly to SBMFF’s over the last 12 months.

SBMFF's P/E Growth Rating (35) in the null industry is somewhat better than the same rating for ARGX (75) in the Pharmaceuticals Other industry. This means that SBMFF’s stock grew somewhat faster than ARGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGXSBMFF
RSI
ODDS (%)
Bearish Trend 3 days ago
43%
Bullish Trend 3 days ago
39%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
54%
Momentum
ODDS (%)
Bearish Trend 3 days ago
60%
Bullish Trend 5 days ago
54%
MACD
ODDS (%)
Bearish Trend 3 days ago
58%
Bullish Trend 6 days ago
56%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
63%
Bullish Trend 3 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
66%
Bullish Trend 3 days ago
63%
Advances
ODDS (%)
Bullish Trend 11 days ago
70%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
63%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
78%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ARGX
Daily Signal:
Gain/Loss:
SBMFF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CHGX27.840.13
+0.49%
EA SERIES TRUST STANCE SUSTAINABLE BETA ETF
BUI26.030.08
+0.31%
BlackRock Utilities Infrastructure & Power Opportunities Trust
CEFD19.310.02
+0.10%
ETRACS Monthly Pay 1.5X Lvgd CE Fd ETN
JMTG51.110.04
+0.08%
JPMorgan Mortgage-Backed Securities ETF
EWT65.92-0.88
-1.32%
iShares MSCI Taiwan ETF

SBMFF and

Correlation & Price change

A.I.dvisor tells us that SBMFF and PSTV have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBMFF and PSTV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBMFF
1D Price
Change %
SBMFF100%
N/A
PSTV - SBMFF
22%
Poorly correlated
+7.11%
BCDA - SBMFF
21%
Poorly correlated
N/A
INKT - SBMFF
21%
Poorly correlated
-1.49%
ALZN - SBMFF
20%
Poorly correlated
+0.93%
LYEL - SBMFF
20%
Poorly correlated
+6.81%
More